FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004337431> ?p ?o ?g. }

• W2004337431 endingPage "168" @default.
• W2004337431 startingPage "160" @default.
• W2004337431 abstract "Ellipticine and benzo(a)pyrene increase their own metabolic activation via modulation of expression and enzymatic activity of cytochromes P450 1A1 and 1A2 Two compounds known to covalently bind to DNA after their activation with cytochromes P450 (CYPs), carcinogenic benzo(a)pyrene (BaP) and an antineoplastic agent ellipticine, were investigated for their potential to induce CYP and NADPH:CYP reductase (POR) enzymes in rodent livers, the main target organ for DNA adduct formation. Two animal models were used in the study: (i) rats as animals mimicking the fate of ellipticine in humans and (ii) mice, especially wild-type (WT) and hepatic POR null (HRN™) mouse lines. Ellipticine and BaP induce expression of CYP1A enzymes in livers of experimental models, which leads to increase in their enzymatic activity. In addition, both compounds are capable of generating DNA adducts, predominantly in livers of studied organisms. As determined by 32 P postlabelling analysis, levels of ellipticine-derived DNA adducts formed in vivo in the livers of HRN™ mice were reduced (by up to 65%) relative to levels in WT mice, indicating that POR mediated CYP enzyme activity is important for the activation of ellipticine. In contrast to these results, 6.4 fold higher DNA binding of BaP was observed in the livers of HRN™ mice than in WT mice. This finding suggests a detoxication role of CYP1A in BaP metabolism in vivo . In in vitro experiments, DNA adduct formation in calf thymus DNA was up to 25 fold higher in incubations of ellipticine or BaP with microsomes from pretreated animals than with controls. This stimulation effect was attributed to induction of CYP1A1/2 enzymes, which are responsible for oxidative activation of both compounds to the metabolites generating major DNA adducts in vitro . Taken together, these results demonstrate that by inducing CYP1A1/2, ellipticine and BaP modulate their own enzymatic metabolic activation and detoxication, thereby modulating their either pharmacological (ellipticine) and/or genotoxic potential (both compounds)." @default.
• W2004337431 created "2016-06-24" @default.
• W2004337431 creator A5009212415 @default.
• W2004337431 creator A5027556209 @default.
• W2004337431 creator A5028762636 @default.
• W2004337431 creator A5055879543 @default.
• W2004337431 creator A5071958130 @default.
• W2004337431 creator A5077879348 @default.
• W2004337431 creator A5087622113 @default.
• W2004337431 date "2008-09-01" @default.
• W2004337431 modified "2023-09-23" @default.
• W2004337431 title "Ellipticine and benzo(a)pyrene increase their own metabolic activation via modulation of expression and enzymatic activity of cytochromes P450 1A1 and 1A2" @default.
• W2004337431 cites W1963847519 @default.
• W2004337431 cites W1964109666 @default.
• W2004337431 cites W1965147058 @default.
• W2004337431 cites W1965162210 @default.
• W2004337431 cites W1977948759 @default.
• W2004337431 cites W1980125338 @default.
• W2004337431 cites W1993084845 @default.
• W2004337431 cites W2000423718 @default.
• W2004337431 cites W2014330039 @default.
• W2004337431 cites W2020389331 @default.
• W2004337431 cites W2021208131 @default.
• W2004337431 cites W2034171802 @default.
• W2004337431 cites W2034607919 @default.
• W2004337431 cites W2043281075 @default.
• W2004337431 cites W2047821701 @default.
• W2004337431 cites W2062934774 @default.
• W2004337431 cites W2088961696 @default.
• W2004337431 cites W2092905174 @default.
• W2004337431 cites W2093852491 @default.
• W2004337431 cites W2098446152 @default.
• W2004337431 cites W2099787373 @default.
• W2004337431 cites W2101372104 @default.
• W2004337431 cites W2119496460 @default.
• W2004337431 cites W2128329009 @default.
• W2004337431 cites W2130251223 @default.
• W2004337431 cites W2167174691 @default.
• W2004337431 doi "https://doi.org/10.2478/v10102-010-0033-z" @default.
• W2004337431 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2993483" @default.
• W2004337431 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21218107" @default.
• W2004337431 hasPublicationYear "2008" @default.
• W2004337431 type Work @default.
• W2004337431 sameAs 2004337431 @default.
• W2004337431 citedByCount "11" @default.
• W2004337431 countsByYear W20043374312013 @default.
• W2004337431 countsByYear W20043374312014 @default.
• W2004337431 countsByYear W20043374312018 @default.
• W2004337431 countsByYear W20043374312019 @default.
• W2004337431 countsByYear W20043374312021 @default.
• W2004337431 countsByYear W20043374312022 @default.
• W2004337431 countsByYear W20043374312023 @default.
• W2004337431 crossrefType "journal-article" @default.
• W2004337431 hasAuthorship W2004337431A5009212415 @default.
• W2004337431 hasAuthorship W2004337431A5027556209 @default.
• W2004337431 hasAuthorship W2004337431A5028762636 @default.
• W2004337431 hasAuthorship W2004337431A5055879543 @default.
• W2004337431 hasAuthorship W2004337431A5071958130 @default.
• W2004337431 hasAuthorship W2004337431A5077879348 @default.
• W2004337431 hasAuthorship W2004337431A5087622113 @default.
• W2004337431 hasBestOaLocation W20043374311 @default.
• W2004337431 hasConcept C108204754 @default.
• W2004337431 hasConcept C114246631 @default.
• W2004337431 hasConcept C153911025 @default.
• W2004337431 hasConcept C178790620 @default.
• W2004337431 hasConcept C181199279 @default.
• W2004337431 hasConcept C185592680 @default.
• W2004337431 hasConcept C202751555 @default.
• W2004337431 hasConcept C207001950 @default.
• W2004337431 hasConcept C2777538855 @default.
• W2004337431 hasConcept C2778951431 @default.
• W2004337431 hasConcept C2779838395 @default.
• W2004337431 hasConcept C2781247443 @default.
• W2004337431 hasConcept C526171541 @default.
• W2004337431 hasConcept C54355233 @default.
• W2004337431 hasConcept C552990157 @default.
• W2004337431 hasConcept C55493867 @default.
• W2004337431 hasConcept C86803240 @default.
• W2004337431 hasConcept C87644729 @default.
• W2004337431 hasConceptScore W2004337431C108204754 @default.
• W2004337431 hasConceptScore W2004337431C114246631 @default.
• W2004337431 hasConceptScore W2004337431C153911025 @default.
• W2004337431 hasConceptScore W2004337431C178790620 @default.
• W2004337431 hasConceptScore W2004337431C181199279 @default.
• W2004337431 hasConceptScore W2004337431C185592680 @default.
• W2004337431 hasConceptScore W2004337431C202751555 @default.
• W2004337431 hasConceptScore W2004337431C207001950 @default.
• W2004337431 hasConceptScore W2004337431C2777538855 @default.
• W2004337431 hasConceptScore W2004337431C2778951431 @default.
• W2004337431 hasConceptScore W2004337431C2779838395 @default.
• W2004337431 hasConceptScore W2004337431C2781247443 @default.
• W2004337431 hasConceptScore W2004337431C526171541 @default.
• W2004337431 hasConceptScore W2004337431C54355233 @default.
• W2004337431 hasConceptScore W2004337431C552990157 @default.
• W2004337431 hasConceptScore W2004337431C55493867 @default.
• W2004337431 hasConceptScore W2004337431C86803240 @default.
• W2004337431 hasConceptScore W2004337431C87644729 @default.
• W2004337431 hasIssue "2" @default.

• next